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symptom levels of anxiety and depression, and sleep impairment
among patients with NeP. METHODS: Participants in an obser-
vational, prospective and multicentre study in Spain (DONEGA
study) with NeP of different etiologies, completed the Short
Form-McGill Pain Questionnaire (SF-MPQ), the Mini Mental
State Examination (MMSE), the COVI Anxiety Scale, the
RASKIN Depression Rating Scale, and the MOS Sleep Scale
(MOS-S) at baseline. RESULTS: A total of 1519 patients above
18 years [mean ± SD; 56.0 ± 13.7 years old (58.8% female)] with
NeP were enrolled in the study. Peripheral NeP was presented in
>95.0% subjects. Patients had NeP for 1.1 ± 2.8 years, and
83.3% were on any type of analgesic treatment at baseline: oral
analgesics (51.2%), topical analgesics (26.9%), NSAID’s
(11.1%), antiepileptics (7.3%), and psychoanaleptics (3.5%).
Average Pain scores were 13.1 ± 8.2pts, 10.0 ± 5.8pts, and 3.1
± 3.3pts, for total scale (range 0–45), sensory domain (range
0–33), and affective domain (range 0–12), respectively. Present
pain intensity was 2.8 ± 1.0 (range 0–5) and mean pain past week
on a VAS scale was 71,2 ± 18,9mm. Pain slightly interfered with
patient mental functioning (average MMSE score; 27.2 ± 3.6pts,
18.0% of patients with MMSE score £ 24pts). Pain interfered
with all sleep attributes, obtaining high scoring in composite
measures; SLP6; 45.3 ± 21.8, and SLP9; 46.8 ± 21.1. The 24.4%
and 15.6% of patients had moderate to severe symptoms levels
of anxiety and depression (RASKIN and COVI scores ≥ 9 on
3–15 scale), with an average depression and anxiety scores of
6.3 ± 3.3pts and 5.4 ± 2.8, respectively. CONCLUSIONS: NeP
decreases patient mental functioning as assessed by MMSE,
while increasing anxiety and depression symptoms and sleep
problems. These ﬁndings substantially deteriorated with pain
severity.
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OBJECTIVES: Utilities for Parkinson’s Disease (PD) are needed
for cost-utility analyses of antiparkinsonian treatments but are
not always available from PD studies. We compared the perfor-
mance of classiﬁcation and regression tree (CART) analysis with
multiple regression for mapping the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) to utilities. METHODS: We used data
from an ongoing prospective cost study of the German Compe-
tence Network for Parkinson Syndromes. Single UPDRS items
were used as predictors for utilities assessed with EuroQoL (EQ-
5D). First, we developed a multiple regression model using
forward selection based on likelihood ratio testing (p < 0.05).
Second, we developed a CART model using t-test statistics as
selection criteria and adjusting p-values for non-dichotomous
variables by the Miller & Siegmund method. The resulting
mutual exclusive and exhausting groups were used as predictors
in a multiple linear regression model. The performance (good-
ness-of-ﬁt) of both approaches was compared using explained
variance (adjusted R-square statistic). RESULTS: The ﬁnal mul-
tiple regression model included a linear combination of three
UPDRS subscore variables (i.e., parts II–IV) and yielded an
adjusted R-square of 0.55. The ﬁnal CART model had three
levels with four variables partitioning the sample into ﬁve sub-
groups. These variables were level of rigidity (UPDRS item 22),
problems arising from a chair (item 27), posture (item 28), and
unpredictable ﬂuctuations (item 36). The mean (median) utility
in the 5 subgroups was 0.90 (0.89), 0.81 (0.89), 0.68 (0.70),
0.66 (0.70), and 0.32 (0.29). The CART model had adjusted R-
square of 0.50. CONCLUSIONS: Multiple regression performed
slightly better than CART when used to predict utilities based
on clinical characteristics of PD patients. Both models were
based on feasible and parsimonious prediction rules with only
three and four variables, respectively. Whereas multiple regres-
sion modeling is the more widely used statistical approach,
CART-based prediction models may be easier to interpret for
physicians.
PNL25
INTERNAL, EXTERNAL,AND CROSS-MODEL VALIDATION OF
A MULTI-OUTCOME DECISION MODEL FOR PARKINSON’S
DISEASE
Siebert U1, Bornschein B2, Dodel R3
1Harvard Medical School, Boston, MA, USA; 2University of Munich,
Munich, Germany; 3Friedrich-Wilhelms-University, Bonn, Germany
OBJECTIVES: We have recently reported on a generic, multi-
outcome disease model for Parkinson’s disease (PD). Now we
present ﬁrst results of internal, external and cross-model valida-
tion. METHODS: Our lifetime PD Markov model simulates a
hypothetical cohort of patients moving through health states
reﬂecting patient characteristics that would be observed in the
absence of treatment (Hoehn&Yahr “off” states [HYoff]). We
used HYoff I-V and death as Markov states. The model is
designed to simultaneously predict multiple outcomes, e.g. time
in Hoehn&Yahr “on” states (HYon) observed under treatment,
quality-adjusted life expectancy (QALE), or complication rates.
As internal validation, we compared time in HYoff stages pre-
dicted by our model to results reported in the progression study
used to derive our input parameters. As external validation, we
compared model results of mean times in HYoff and HYon states
with extern literature data not used in our model. Finally, we
cross-validated our model comparing QALE under levodopa
treatment with QALE of other published models reporting this
outcome. RESULTS: Internal validation of HYoff input data
showed a 97.4–99.9% accuracy. Although external validation of
average HYoff progression rates overestimated external popula-
tion data from Hoehn & Yahr (1967) by 19%, the mean HYon
progression rate predicted by our model (0.42 HY stages/y)
matched well with estimates reported in the literature (0.40 HY
stages/y). After restricting our model to a 5-year time horizon,
discounted QALYs exceeded those from 2 other published
models by 24% and 35%. This differences were mostly attrib-
utable to different Markov state-speciﬁc utilities. As other
Markov models for drug treatment did not evaluate QALE, we
could not cross-validate for this outcome. CONCLUSIONS: Our
PD model is internal valid and closely reproduces external data
for progression under standard treatment. Variability in QALE
are due to a combination of different model design, state-speciﬁc
utilities, and underlying study populations.
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OBJECTIVES: Assess the clinimetric properties of the
MIGRAINE-SCREEN-Q (MS-Q) questionnaire for the screen-
ing of patients with migraine in the general population.
METHODS: A 16-item tool was developed from the Interna-
tional Headache Criteria (IHS) of Migraine and a review of the
literature by a panel of 6 experts in neurology, occupational med-
icine, clinimetrics, and methodology. The MS-Q instrument was
mailed and ﬁlled in by the employees working for at least 3
months at the Pﬁzer company (Step I) and self-administered to
patients of a Neurological Clinic (Step II and III) in Spain. All
subjects were subsequently referred for an independent diagno-
sis by a neurologist, blinded of MS-Q results. The diagnosis was
assigned according to IHS criteria. Statistical methods included
logistic regression, ROC curves analysis and determination of
sensitivity, speciﬁcity, and positive and negative predictive values
with its 95% conﬁdence interval. RESULTS: In all, 415 employ-
ees (Step I) and 50 patients (Step II) were recruited. Of them,
325 subjects were evaluable and diagnosed as having migraine
(n = 85), other headaches (n = 80) and non-headache subjects (n
= 160). A further 140 patients were recruited in a Neurological
Clinic and analysed independently to get a sample of 70 migraine
and 70 non-migraine patients (Step III). A ﬁve-item subset
(headache frequency and severity, 4 hours’ to 3 days’ duration,
nausea, sensitivity to light/noise and disability) out of 16 pre-
liminary items was derived by logistic regression analyses. A cut-
off of 4 or more points provided a sensitivity of 0.93 (95%CI,
0.87–0.99), speciﬁcity of 0.81 (0.72–0.91), a positive predictive
value of 0.83 (0.75–0.91) and a negative predictive value of 0.92
(0.85–0.99). The reliability Cronbach Alpha coefﬁcient was
0.82. CONCLUSIONS: The 5-item MIGRAINE SCREEN-Q
instrument was found to be a valid and reliable screening tool
for migraine headaches. Further studies are warranted to test its
applicability in the general population.
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OBJECTIVE: IRLS is used for clinical assessment and severity
of Restless Legs Syndrome (RLS). To compare the burden of RLS
with other health states, this study has mapped the IRLS to a
multi-attribute utility measure, the EQ-5D. METHODS: Four
RLS experts from Spain, France, UK and US were identiﬁed to
participate in mapping the ten IRLS items (each with ﬁve ordinal
response levels) to the ﬁve EQ-5D domains (each with three
ordinal response levels). A pilot study conducted by one expert
identiﬁed two issues: 1) the disease characteristics of RLS and
the 10 IRLS items could not be mapped to EQ-5D domains of
“Self-care” and “Mobility” (EQ-5D level “1” was assigned to
both), and 2) IRLS question three (relating to relief from move-
ment) proved difﬁcult to map; an algorithm to map this was
developed. All experts then completed their individual mapping
responses. Discrepancies were resolved through consensus result-
ing in one ﬁnal mapping response. RESULTS: The experts con-
cluded that the EQ-5D domains of “Pain/Discomfort”, “Usual
Activities” and “Anxiety/Depression” were appropriate for
mapping to the 10 IRLS items (each item mapped once).
“Pain/Discomfort” mapped to four IRLS items, “Usual Activi-
ties” mapped to ﬁve IRLS items and “Anxiety/Depression”
mapped to one IRLS item. Ordinal responses for each IRLS item
were mapped to appropriate ordinal responses on the three EQ-
5D domains. EQ-5D utilities could be established for different
combinations of IRLS item responses and corresponding IRLS
total scores. Using trial data, a signiﬁcant correlation between
IRLS total scores and EQ-5D utilities was established (r = -0.84,
p < 0.0001). CONCLUSION: Based on clinical consensus, the
IRLS can be successfully mapped to the EQ-5D. The algorithm
resulting from this work may be used to compare health related
QoL of RLS sufferers with those of other diseases for resource
allocation decisions.
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OBJECTIVES: The development of Markov decision models for
chronic diseases is often time-consuming and sophisticated.
Therefore, generic and ﬂexible models have advantages. We
present a method that allows to externally adjust decision models
for context-speciﬁc variables such as epidemiologic, clinical, or
economic parameters. METHODS: To allow transfer of decision
models across populations or countries with correct adjustment
for context-speciﬁc parameters, we used centered regression
equations instead of ﬁxed values as model parameters. Clinical
event probabilities, utilities, and costs were deﬁned as functions
of context-speciﬁc predictors. Centering the predictors on their
means allows to interpret intercepts as grand means and regres-
sion coefﬁcients as relative modiﬁers. We applied this approach
to the Parkinson’s Disease Model (PDM) using 1-year follow-up
data of target outcomes (clinical events, utilities [EQ-5D], and
costs) from the German Parkinson’s Disease Competence
Network Study (n = 145). We validated the centered regression
approach by comparing model results to those from models with
model parameters based on non-centered regression and ﬁxed
parameters values. RESULTS: Target outcomes of PDM were
deﬁned by 1) centered regression equations; 2) intercepts repre-
senting grand means of 1-year target outcomes (anchor value);
3) distribution of disease severity stages; and 4) regression coef-
ﬁcients for each stage representing additive (utilities) or multi-
plicative (events, costs) modiﬁers for the anchor value. Assuming
constant modiﬁers, the model can be transferred if data on mean
outcomes and severity stage distribution of the target country are
available. Sensitivity analyses were facilitated, as changes in
overall event risk, utilities, or costs were achieved by simply
changing intercepts. Validation of the centered regression-based
PDM with non-centered regression equations or using ﬁxed
values in the model led to identical results. CONCLUSIONS:
The implementation of centered regression-based equations in a
decision model enhances model ﬂexibility with respect to sensi-
tivity analyses and transferability to another population or
health care context.
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OBJECTIVES: Estimating the cost of a disease for Europe is a
methodological challenge due to differences in epidemiology,
